Ballew Advisors Inc Cuts Stock Holdings in GSK plc (NYSE:GSK)

Ballew Advisors Inc cut its stake in GSK plc (NYSE:GSK) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,758 shares of the pharmaceutical company’s stock after selling 372 shares during the period. Ballew Advisors Inc’s holdings in GSK were worth $319,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of GSK. FMR LLC increased its position in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of GSK during the second quarter worth $52,487,000. Fisher Asset Management LLC increased its holdings in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares during the last quarter. Hotchkis & Wiley Capital Management LLC raised its stake in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in GSK by 33.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock worth $86,875,000 after buying an additional 569,614 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GSK has been the topic of several research analyst reports. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

GSK stock opened at $33.46 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $69.34 billion, a P/E ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. The business has a 50 day simple moving average of $34.02 and a 200-day simple moving average of $37.98. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a dividend of $0.3928 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.70%. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is currently 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.